Discussion about this post

User's avatar
John Petersen's avatar

Monetizing basic research has always been a fools errand. For example going back to1992, research into the cockroach microbiome was still in its early stages. "A key study published that year focused on the contribution of anaerobic protozoa and methanogens to the hindgut metabolism of the American cockroach (Periplaneta americana)." Of course many in Congress would have made fun of this early microbiome research. Thirty years later, built on the shoulders of cockroaches (and other lesser species), human microbiome research is well underway but has yet to lead to significant paradigm shifts in human healthcare. Per your quantum example, there was a substantial lag between quantum physics and smart phones.

An enormous effort needs to go into basic research to build to the point that monetization/societal benefit is achieved (of course along the way a bunch of scientists had fun figuring things out). US government investment needs to keep contributing to this base on which product development can be built. Essentially decide to commit to x% of budget on research and just keep plugging away across a variety of disciplines. No one can know what will pay off, but statistically research will pay off.

Even once the development opportunity is created, the big money goes to the group that solves the "last" problem, not to the first mover. So in my view the most productive ecosystems need to have small risk takers (not invested in the status quo) as well as established players who can buy out and the complete the development of innovative products. Hard to think that any central government (or large corporation) will be sufficient in and of itself to provide a steady stream of innovation. Neither the Chinese or large corporations will fail for lack of trying.

Max's avatar

Excellent overview; three quick follow-up questions/comments: (1) in light of involution, how can private Chinese firms appropriate their investments in R&D? (2) in light of consortia sharing, isn't substantial free-riding likely, and if not, are there different legal or cultural constraints at work that prevent free-riding? and (3) what role does competition play, if any, at the R&D stage, and, if present, is it competition among firms, bureaucracies or regions, or all of the above? Certainly the framework for evaluating innovation and incentives (from Schumpeter to Arrow to our recent Nobel prize winners) tends to focus on competition among firms. China's approach suggests either that the economic modeling is incomplete or that their approach will have problems progressing to next-generation products. We shall see.

56 more comments...

No posts

Ready for more?